Evinacumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Evinacumab: From Homozygous Familial Hypercholesterolaemia to Diabetic Cataract
One-Sentence Summary
Evinacumab is a monoclonal antibody targeting ANGPTL3, approved internationally (including by the EMA as Evkeeza) for homozygous familial hypercholesterolaemia (HoFH). The TxGNN model predicts it may be effective for Diabetic Cataract, however there are currently 0 clinical trials and 0 publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Homozygous familial hypercholesterolaemia (HoFH) — based on EMA centralised authorisation; no Danish national authorisation on record |
| Predicted New Indication | Diabetic Cataract |
| TxGNN Prediction Score | 98.52% |
| Evidence Level | L5 (Model prediction only, no human studies) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack. Based on known information, evinacumab is a fully human monoclonal antibody that inhibits angiopoietin-like protein 3 (ANGPTL3). By blocking ANGPTL3, evinacumab reduces levels of LDL cholesterol, HDL cholesterol, and triglycerides through pathways independent of the LDL receptor. It has been approved by the EMA (as Evkeeza) and the US FDA for the treatment of homozygous familial hypercholesterolaemia.
The TxGNN model predicts a potential link to diabetic cataract, presumably because diabetes-associated cataracts involve metabolic dysregulation — including lipid metabolism abnormalities — and ANGPTL3 sits at a crossroads of lipid and glucose metabolic pathways. Diabetic cataracts develop through sorbitol accumulation via the polyol pathway and through glycation of lens crystallin proteins, processes that are exacerbated by the metabolic milieu of diabetes. Lipid deposits in the lens and oxidative stress secondary to dyslipidaemia may also contribute to lens opacification.
However, the mechanistic link between ANGPTL3 inhibition and cataract prevention or reversal remains entirely speculative. There is no published preclinical or clinical evidence that lowering circulating lipids via ANGPTL3 blockade affects lens transparency or the progression of diabetic cataract. Furthermore, evinacumab is administered intravenously as a large-molecule biologic, and achieving therapeutic concentrations in the avascular lens would be a significant pharmacokinetic challenge. The remaining predicted indications (immature cataract, mature cataract, craniostenosis cataract, tetanic cataract) all lack any mechanistic rationale connecting ANGPTL3 inhibition to lens pathology.
Clinical Trial Evidence
Currently no related clinical trials registered for evinacumab in any cataract-related indication. Searches were performed on ClinicalTrials.gov and the WHO ICTRP registry (query date: 2026-03-24) for all ten predicted indications, yielding zero results.
Literature Evidence
Currently no related literature available. PubMed searches (query date: 2026-03-24) for evinacumab combined with each predicted cataract indication returned zero publications.
Denmark Market Information
Evinacumab currently holds no national marketing authorisation from the Danish Medicines Agency (Lægemiddelstyrelsen) and is not marketed in Denmark. The EMA has granted a centralised marketing authorisation for Evkeeza (evinacumab) for HoFH; however, it does not appear in the available Danish licence registry data.
| Marketing Authorisation Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| EU/1/21/1551 (EMA centralised) | Evkeeza | Concentrate for solution for infusion | Homozygous familial hypercholesterolaemia (HoFH) as adjunct to other lipid-lowering therapies |
Note: The above EMA authorisation is referenced for completeness. No national Danish licences were found in the evidence pack.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. The current evidence pack does not contain warnings, contraindications, or drug interaction data for evinacumab. The EMA-approved SmPC for Evkeeza should be consulted for the complete safety profile.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is based solely on TxGNN model output (Evidence Level L5) with no supporting clinical trials, literature, or preclinical data. The mechanistic link between ANGPTL3 inhibition and diabetic cataract is speculative at best — cataract pathogenesis is driven primarily by lens protein glycation and the polyol pathway, not by circulating lipid levels. Additionally, evinacumab is a large-molecule intravenous biologic with no established mechanism to reach the avascular lens at therapeutic concentrations. The drug is also not currently marketed in Denmark, adding a significant access barrier.
To proceed, the following would be needed:
- Preclinical evidence demonstrating that ANGPTL3 inhibition affects lens transparency or cataractogenesis in diabetic animal models
- Pharmacokinetic data establishing that evinacumab (or its effects) can reach the lens compartment
- Detailed mechanism of action analysis linking lipid metabolism modulation to diabetic cataract pathophysiology
- At minimum one observational study or case series suggesting a signal of reduced cataract incidence in patients receiving evinacumab for HoFH
- Complete safety profile review including SmPC warnings and contraindications
This report is for research purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.